Apimeds Pharmaceuticals Us, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
Apimeds Pharmaceuticals US, Inc. announced the completion of its merger with MindWave Innovations Inc., integrating a digital asset treasury platform alongside its biopharmaceutical business.
AMEX
10-K/A: Apimeds Pharmaceuticals US, Inc. Files Amended 10-K to Correct Disclosure on Internal Controls
Apimeds Pharmaceuticals US, Inc. files an amendment to its annual report to disclose that its disclosure controls and procedures were not effective as of December 31, 2024, due to material weaknesses in internal controls over financial reporting.
AMEX
Apimeds Pharmaceuticals US, Inc. outlines its capital stock, voting rights, and regulatory environment in its annual report, emphasizing its focus on developing Apitox for osteoarthritis and multiple sclerosis.